If you work with injured clients, you have probably been asked about BPC-157. It turns up in podcasts, gym conversations and athlete interviews as a peptide that supposedly speeds up tendon, ligament and muscle repair. Some clients have already tried it. Others want to know whether they should.
The honest answer starts with the tissue itself, then looks at what the BPC-157 research actually covers. The gap between the two explains both why the peptide attracts so much interest and why the evidence is not yet strong enough to justify the hype.
Why tendons and ligaments heal so slowly
Muscle has a rich blood supply and a population of satellite cells ready to repair damage. Tendons and ligaments are different. They are dense, highly organized bundles of type I collagen with relatively few cells and comparatively poor vascularity, especially in watershed zones such as the mid-portion of the Achilles tendon or the critical zone of the supraspinatus.
Healing follows three overlapping phases. In the inflammatory phase, over the first few days, blood cells and inflammatory mediators clear debris and release growth factors. In the proliferative phase, over the following weeks, fibroblasts multiply and lay down new collagen, much of it the weaker, disorganized type III. In the remodeling phase, which can last many months, that tissue is gradually replaced with type I collagen and realigned along the lines of stress.
The result is rarely as good as the original. Healed tendon is often stiffer, weaker and more prone to re-injury, which is why rehabilitation focuses so heavily on progressive loading. Mechanical load is one of the main signals that tells fibroblasts how to align the new collagen.
That slow, imperfect process is exactly why a compound claiming to speed things up gets attention.
What BPC-157 is
BPC-157 is a synthetic peptide made of fifteen amino acids. Its sequence was taken from a larger protein found in human gastric juice, which is where the name “body protection compound” comes from. Most of the early research came from a single group at the University of Zagreb, initially studying it for stomach and intestinal protection before moving on to other tissues.
It is not an approved medicine anywhere in the US, the UK, Canada or Australia. It is sold online as a research chemical, usually as freeze-dried powder in small vials.
What the animal research shows
The bulk of the evidence comes from rats. Researchers have cut or crushed Achilles tendons, medial collateral ligaments and muscles in rats, given some animals BPC-157 and compared the healing. In many of these studies, the treated animals showed better functional recovery, stronger tissue and more organized collagen on histology.
Laboratory work on cells has suggested some possible mechanisms. Studies on rat tendon fibroblasts found that BPC-157 increased their outgrowth and migration, apparently through the FAK-paxillin signaling pathway involved in cell movement. Other work found it increased the expression of growth hormone receptors on tendon fibroblasts. A separate line of research points to effects on blood vessel formation through VEGF receptor signaling, which would matter a great deal in poorly vascularized tissue.
Taken together, it is a coherent and intriguing picture. It is also almost entirely preclinical.
What the human research shows
Very little. There are no large randomized controlled trials of BPC-157 for musculoskeletal injury in humans. The human data that exist consist of small case series and pilot reports, including a retrospective look at a small group of patients with knee pain who received injections. Studies like that cannot separate the peptide’s effect from placebo, natural recovery or other treatments the patients received at the same time.
Rat tendon is also not human tendon. Rodents heal faster, the injuries in these studies are created in controlled conditions, and many promising animal results in musculoskeletal medicine have not held up in people.
The regulatory and sporting picture
In 2023, the US FDA placed BPC-157 on a list of substances that compounding pharmacies should not use, citing a lack of safety information. That decision is part of an ongoing review, but for now it means clients cannot get it through a normal prescription route in the US.
For athletes, there is a more immediate issue. The World Anti-Doping Agency lists BPC-157 as a prohibited substance under its category for non-approved substances, so any client subject to drug testing risks a violation by using it.
Quality is another unknown. Because BPC-157 is bought from online sellers rather than pharmacies, the contents of a vial depend entirely on the seller. Lab reports vary widely in what they test, and some are reused across batches or cannot be verified at all.
How to talk to clients about it
For massage therapists, personal trainers and other manual therapy professionals, BPC-157 sits outside scope of practice. Recommending it, sourcing it or advising on its use is not part of the job, and it is worth saying that clearly if a client asks.
What you can do is give an honest summary. The animal research is interesting. The human evidence is thin. It is banned in tested sport. Its quality depends on an unregulated seller. And it is no substitute for the things that are known to help soft tissue heal: appropriate rest early on, progressive loading, good sleep, adequate protein and time.
If a client is determined to explore it, the right referral is to a physician who can consider their medical history and discuss the risks directly. If they are already using it, encourage them to tell their doctor.
Soft tissue healing is slow, and clients understandably want something to speed it up. The most useful thing a practitioner can offer is a clear sense of what the evidence supports, so clients can make decisions with their eyes open.
Written by Manuel Paradela (publications@bazoom.com)
